Loading...
•
Dec 31, 2021
Sangamo Q4 2021 Earnings Report
Reported fourth quarter and full year 2021 financial results and recent business highlights.
Key Takeaways
Sangamo Therapeutics reported a net loss of $37.5 million, or $0.26 per share, for the fourth quarter ended December 31, 2021. Revenues for the quarter were $28.0 million, compared to $25.8 million for the same period in 2020. The company is advancing its genomic medicines pipeline and has fully operational AAV and cell therapy manufacturing facilities.
Updated preliminary Phase 1/2 data for Fabry disease gene therapy showed continued safety, tolerability, and elevated α-Gal A enzyme activity, with Phase 3 planning initiated.
Updated preliminary Phase 1/2 data for sickle cell disease gene-edited cell therapy showed proof-of-concept safety, tolerability, and efficacy results.
Updated Phase 1/2 results for hemophilia A gene therapy showed sustained bleeding control in the highest dose cohort through two years of follow-up.
First patient enrolled in Phase 1/2 study for renal transplant rejection CAR Treg cell therapy.
Forward Guidance
Sangamo expects total operating expenses in the range of approximately $320 million to $350 million in 2022 on a GAAP basis. Non-GAAP total operating expenses, excluding estimated non-cash stock-based compensation expense of approximately $40 million, are expected to be in the range of approximately $280 million to $310 million in 2022.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...